128 results
10-Q
2024 Q1
EX-10.1
SKYE
Skye Bioscience Inc
Quarterly report
10 May 24
4:02pm
8-K
EX-10.2
SKYE
Skye Bioscience Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-10.1
SKYE
Skye Bioscience Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-10.1
SKYE
Skye Bioscience Inc
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
8-K
EX-10.2
SKYE
Skye Bioscience Inc
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
8-K
EX-10.1
jiwgduoty1kr
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-10.2
oeh00yd rr
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-10.1
3fcvtl jn2jym9ygki
3 Oct 23
Departure of Directors or Certain Officers
4:34pm
8-K
EX-10.3
h5kc yy92avltd01j5r5
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.4
qcveo rz4jskj
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.2
ukwxg
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.1
0yrym17vka
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.1
0hdwt
23 Feb 23
Entry into a Material Definitive Agreement
5:18pm
8-K
EX-10.1
v838i0jwjy
15 Feb 23
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
4:26pm
8-K
EX-10.1
0z6zv0939tflf
26 Jan 23
Entry into a Material Definitive Agreement
9:22pm
8-K
EX-10.1
tu26g3gn
6 Jan 23
Entry into a Material Definitive Agreement
4:57pm
8-K
EX-10.1
hbiijrc3j z7
16 Dec 22
Entry into a Material Definitive Agreement
6:40pm